Making Intracellular Biologics a Reality

Entrada Therapeutics is a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics

Discover

Discover the science behind our approach

Meet

Meet the leadership team at Entrada Therapeutics

Learn

Learn about the work we are doing

News & Press Releases

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

BOSTON, Mass., Dec. 18, 2018 – Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced it has raised $59 million in a Series A financing.

Read more
December 18, 2018
More news